INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) said that the new Phase 3 data for Tradjenta (linagliptin) tablets in black or African American patients with type 2 diabetes showed significant improvement in blood sugar.
According to the company, the Phase 3 study results for linagliptin 5 mg once-daily showed significant hemoglobin A1c reduction of 0.88 percent compared to 0.24 percent in the placebo group at 24 weeks in black or African American adult patients with type 2 diabetes whose blood sugar was not adequately controlled.
'These findings support the efficacy and safety profile of linagliptin as a treatment option for African American adult patients with type 2 diabetes,' said lead investigator James Thrasher, Arkansas Diabetes and Endocrinology Center. 'As there may be differences in response to treatment among ethnic groups, an important finding of this trial is that the results are consistent with the A1C reduction seen in the linagliptin pivotal trials, which included a small sample of African American patients.'
Linagliptin is marketed as Tradjenta 5mg once-daily tablets in the U.S., and is the first and only member of the dipeptidyl peptidase-4 inhibitor class to be approved at one dosage strength.
In January 2011, Boehringer Ingelheim Pharmaceuticals, Inc. and and Eli Lilly announced an alliance in the field of diabetes that centers on four pipeline compounds representing several of the largest treatment classes.
Copyright RTT News/dpa-AFX